nitroimidazole (TBA-354) / Global Alliance for TB Drug Development - LARVOL DELTA

Inhaled Adjunct Therapy with Second-Line Drug Candidates for Dose Reduction in Chemotherapeutic Regimens for Multi-drug-Resistant Tuberculosis. (PubMed, AAPS PharmSciTech) - "We prepared dry powder inhalation (DPI) formulations comprising sutezolid (SUT), the second-generation pretomanid analog TBA-354 (TBA), or a fluorinated derivative of TBA-354 (32,625) in a matrix of the biodegradable polymer poly(L-lactide). The addition of 0.25-0.5 mg/kg/day of SUT, TBA-354, or 32,625 as DPI to oral doses of 50 mg/kg/day was non-inferior in clearing Mtb from the lungs of infected mice. We concluded that adjunct therapy with inhaled second-line agents has the potential to reduce the efficacious oral dose."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Concomitant Medications May Affect the Response to Immune Checkpoint Inhibitor Therapy (ASCO Daily News) - "'The main objective was to assess the potential impact of acetaminophen on efficacy of immunotherapy in patients [with cancer],' Dr. Italiano said in an interview...'This is the first study looking at the effects of acetaminophen on ICIs'....Diwakar Davar, MD...noted that the finding about how acetaminophen can negatively impact the outcomes of patients treated with ICI therapy is provocative, and aligns with reports of reduced immunogenicity following vaccination, including SARS-CoV-2, but that it needs confirmation in additional studies."

Checkpoint inhibition • Interview